APLN and metabolic syndrome: As observed in Table 2, the subgroup findings showed that the apelin levels in studies with a cohort or cross-sectional design, without medical comorbidities of diabetic/metabolic syndrome (MetS), plasma body fluid, patients with other disease, and studies conducted in Europe or Asia were statistically significant when compared to other strata.